RT Journal Article
SR Electronic
T1 Intratumoral administration of CD1c (BDCA-1)<sup>+</sup> and CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005141
DO 10.1136/jitc-2022-005141
VO 10
IS 9
A1 Julia Katharina Schwarze
A1 Jens Tijtgat
A1 Gil Awada
A1 Louise Cras
A1 Angela Vasaturo
A1 Christopher Bagnall
A1 Ramses Forsyth
A1 Inès Dufait
A1 Sandra Tuyaerts
A1 Ivan Van Riet
A1 Bart Neyns
YR 2022
UL http://jitc.bmj.com/content/10/9/e005141.abstract
AB Markup server — Error Error There was a problem handling your request. Please try again in a few minutes, or contact us if you continue to experience this problem.